title: Lenalidomide in myeloma.
abstract: The standard treatment approach to symptomatic myeloma consists of induction therapy, consolidation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation in appropriate patients, maintenance therapy, and salvage therapy. Salvage therapy is of particular importance because not all patients respond to primary therapy, and relapse is virtually universal in responding patients. Newer agents such as thalidomide, bortezomib, and lenalidomide are very active in patients with relapsed or refractory disease. Their use singly and in combination results in excellent cytoreduction including complete remissions in patients relapsing - even after extensive prior therapy. These novel agents have been usually used as salvage therapy in patients relapsing after standard treatment options including transplantation; a setting in which they are thought to improve survival. However, there is an increasing trend to start using them early in the course of the disease; for induction therapy. While early deployment of these agents is certainly associated with high-response rates, evidence that this improves long-term outcome (survival) in patients who subsequently undergo intensive therapy and transplantation is lacking. Toxicity, expense, and possible long-term consequences on the biology of the disease (for example, development of refractory relapse) remain a concern. The most appropriate use of newer agents such as lenalidomide is as salvage therapy of relapsed or refractory disease, and their use as part of induction therapy should be confined to clinical trials until additional data and long-term follow-up are available.
authors: The Feinberg School of Medicine, The Robert H Lurie Comprehensive Cancer Center, Northwestern University, 676 N St Clair Street, Suite 850, Chicago, IL 60611, USA. s-singhal@northwestern.edu
authors: Seema
authors: S
authors: Singhal
authors: Jayesh
authors: J
authors: Mehta
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy*; D012008:Recurrence; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide
references: J Clin Oncol. 2006 Jan 20;24(3):431-6
references: 16365178
references: Blood. 2001 Jul 15;98(2):492-4
references: 11435324
references: Ann Oncol. 2006 Dec;17(12):1766-71
references: 16980599
references: Blood. 2000 Nov 1;96(9):2943-50
references: 11049970
references: N Engl J Med. 2006 May 11;354(19):2079-80
references: 16687729
references: Blood. 2002 Jun 15;99(12):4525-30
references: 12036884
references: Blood. 2006 Nov 15;108(10):3289-94
references: 16873668
references: N Engl J Med. 2006 May 11;354(19):2079-80
references: 16696148
references: N Engl J Med. 2003 May 8;348(19):1875-83
references: 12736280
references: Blood. 2001 Jul 1;98(1):210-6
references: 11418482
references: N Engl J Med. 1999 Nov 18;341(21):1565-71
references: 10564685
references: Curr Treat Options Oncol. 2003 Jun;4(3):229-37
references: 12718800
references: Blood. 2005 Dec 15;106(13):4050-3
references: 16118317
references: Br J Haematol. 2006 Oct;135(2):158-64
references: 16939489
references: Lancet. 2006 Mar 11;367(9513):825-31
references: 16530576
references: Blood. 1999 Jan 1;93(1):55-65
references: 9864146
references: Arch Dermatol. 2006 Oct;142(10):1298-302
references: 17043184
references: J Immunol. 1999 Jul 1;163(1):380-6
references: 10384139
references: N Engl J Med. 2003 Jun 26;348(26):2609-17
references: 12826635
references: Blood. 2006 Nov 15;108(10):3458-64
references: 16840727
references: Bone Marrow Transplant. 2002 Nov;30(10):673-9
references: 12420206
references: Clin J Am Soc Nephrol. 2006 Nov;1(6):1322-30
references: 17699365
references: Blood. 2002 Nov 1;100(9):3063-7
references: 12384400
references: N Engl J Med. 2003 Dec 25;349(26):2495-502
references: 14695409
references: Bioorg Med Chem Lett. 1999 Jun 7;9(11):1625-30
references: 10386948
references: Blood. 1998 Nov 1;92(9):3131-6
references: 9787148
references: Bone Marrow Transplant. 1998 Nov;22(9):835-43
references: 9827810
references: Blood. 2002 May 1;99(9):3163-8
references: 11964279
references: N Engl J Med. 1996 Jul 11;335(2):91-7
references: 8649495
references: N Engl J Med. 2005 Jun 16;352(24):2487-98
references: 15958804
references: Hematol J. 2003;4(6):379-98
references: 14671610
references: Blood. 2005 Dec 1;106(12):3755-9
references: 16105975
references: Mayo Clin Proc. 2007 Oct;82(10):1179-84
references: 17908524
references: N Engl J Med. 2006 Mar 9;354(10):1021-30
references: 16525139